Compare Mongodb Inc (MDB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Neurocrine Biosciences Inc — how do they compare? Mongodb Inc trades at $372 (market cap $29.24B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Mongodb Inc is far larger — about 2× Neurocrine Biosciences Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MDB | NBIX | |
|---|---|---|
Market Cap | $29.24B | $14.60B |
Volume | 1,304,995 | 1,075,694 |
Sector | Technology | Health |
52-Week High | $472.29 | $185.50 |
52-Week Low | $225.95 | $123.10 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $26.86B | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $371.35, up 2.95% today, showing strong momentum despite recent volatility. The stock faces bearish technical signals with resistance at $373, while fundamentals reveal impressive revenue growth from $1.7B to $2.0B in 2025, though net losses persist. Recent investor day highlighted AI product launches and raised long-term targets, but CEO transition creates uncertainty. Analyst consensus remains strongly bullish with $457 price target.
MDB presents a growth-at-a-price scenario with premium valuations (P/E 511) offset by strong revenue momentum and AI positioning. Near-term risks include leadership transition execution and competitive pressures, while the 80% buy rating suggests Wall Street sees 23% upside potential. Investors must weigh expensive multiples against transformative AI opportunities in database market.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
